Tapentadol: An initial analysis

Journal of Opioid Management

Volumn 6, Issue 3, 2010, Pages 223-226

  Prommer, Eric E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Affinity; Neuropathic; Tapentadol

Indexed keywords

CYTOCHROME P450; MORPHINE; NALOXONE; NEUROTRANSMITTER; OXYCODONE; TAPENTADOL; YOHIMBINE;

ANALGESIA; ARTHRALGIA; BONE PAIN; CONSTIPATION; DIZZINESS; DRUG COST; DRUG EFFECT; DRUG FORMULATION; DRUG METABOLISM; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; OSTEOARTHRITIC PAIN; POSTOPERATIVE PAIN; REVIEW; SOMNOLENCE; TOOTH PAIN; VOMITING;

ANALGESICS; ANIMALS; DRUG INTERACTIONS; HUMANS; NOREPINEPHRINE; OSTEOARTHRITIS; PAIN; PHENOLS; RECEPTORS, OPIOID, MU; SEROTONIN;

EID: 77954617741     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0020     Document Type: Review

References (10)

1. Tzschentke TM, Christoph T, Kogel B, et al.: (-)-(1R,2R)-3-(3- Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): A novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276.
2. Tapentadol (Nucynta) - A new analgesic. Med Lett Drugs Ther. 2009; 51(1318): 61-62.
3. Terlinden R, Ossig J, Fliegert F, et al.: Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet. 2007; 32(3): 163-169.
4. Prommer EE: Tramadol: Does it have a role in cancer pain management? J Opioid Manag. 2005; 1(3): 131.
5. Kneip C, Terlinden R, Beier H, et al.: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67-75.
6. Hartrick C, Van Hove I, Stegmann JU, et al.: Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31(2): 260-271.
7. Hale M, Upmalis D, Okamoto A, et al.: Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double-blind study. Curr Med Res Opin. 2009; 25(5): 1095-1104.
8. Daniels S, Casson E, Stegmann JU, et al.: A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009; 25(6): 1551-1561.
9. Kleinert R, Lange C, Steup A, et al.: Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled study. Anesth Analg. 2008; 107(6): 2048-2055-
10. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004; 43(13): 879-923.